Heinrich MC, Blay JY, Gelderblom H, George S, Schöffski P, von Mehren M, Zalcberg JR, Jones RL, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Boye K, Goldstein D, Sánchez C, Siontis BL, Cox P, Davis E, Sherman ML, Ruiz-Soto R, Bauer S (2025)
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
J Clin Oncol, JCO2402818 (in press)
DOI 10.1200/JCO-24-02818, PubMed 40408605

Bjørnerud B, Wesche J, Haugsten EM (2025)
A rhabdomyosarcoma cell migration inhibitor screen using phase-contrast microscopy
Exp Cell Res, 449 (1), 114582
DOI 10.1016/j.yexcr.2025.114582, PubMed 40320199

Yip D, Zalcberg J, Blay JY, Eriksson M, Espinoza D, Price T, Marreaud S, Italiano A, Steeghs N, Boye K, Underhill C, Gebski V, Simes J, Gelderblom H, Joensuu H (2025)
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial
Br J Cancer, 132 (10), 897-904
DOI 10.1038/s41416-025-02983-w, PubMed 40133509